Kyselina Zoledrónová Stada

Zoledronic Acid, the active ingredient in Kyselina Zoledrónová Stada, is a bisphosphonate presented as an injectable solution for intravenous use. It is used to treat osteoporosis, Paget's disease of bone, bone metastases, and hypercalcemia of malignancy in adult patients.

GNH USA supplies Kyselina Zoledrónová Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, conforming to EU quality standards and distributed globally.

Zoledronic Acid is a bisphosphonate that inhibits bone resorption, making it useful in several bone‑related conditions.

- Osteoporosis: reduces risk of vertebral and hip fractures by decreasing bone turnover. - Paget's disease of bone: normalizes bone remodeling and alleviates pain. - Bone metastases: prevents skeletal‑related events and reduces bone pain in cancer patients. - Hypercalcemia of malignancy: lowers elevated serum calcium levels rapidly.

Zoledronic Acid may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Flu‑like symptoms: fever, chills, muscle aches. - Nausea or vomiting. - Transient elevation of serum creatinine. - Headache. - Arthralgia or joint pain. - Injection site discomfort.

Serious or Rare Side Effects: - Osteonecrosis of the jaw (ONJ). - Atypical femoral fractures. - Severe renal impairment or acute renal failure. - Hypocalcemia. - Severe hypersensitivity reactions (anaphylaxis, angioedema).

When using Zoledronic Acid, several precautions should be observed to minimize risks. - Renal function assessment: evaluate baseline creatinine clearance before infusion. - Calcium and vitamin D status: correct deficiencies prior to treatment. - Dental health: perform dental examination and treat existing infections before therapy. - Concomitant medications: avoid concurrent nephrotoxic drugs when possible. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; limited data available. - Store at ambient temperature: keep in original container, protect from moisture and light.

Zoledronic Acid can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., aminoglycosides, NSAIDs): increase risk of renal injury. - Concomitant bisphosphonates: additive bone toxicity. - Calcium or vitamin D supplements administered within 30 minutes of infusion: reduce drug absorption.

Moderate Interactions (Monitor Closely): - Loop diuretics: may exacerbate hypocalcemia. - Antacids containing aluminum or magnesium: may interfere with infusion tolerability. - Corticosteroids: may increase risk of osteonecrosis of the jaw. - Chemotherapy agents (e.g., cisplatin): monitor renal function closely.